Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07067463 · ClinicalTrials.gov registry record · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis (MS) Primary Progressive, sponsored by Zenas BioPharma (USA).
- Recruiting
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 2
- Study locations
NCT07067463 is a Phase 3 study of Multiple Sclerosis (MS) Primary Progressive that is actively recruiting participants, run by Zenas BioPharma (USA). The registered enrollment target is 705 participants, above the 138-participant average among 3 other Multiple Sclerosis (MS) Primary Progressive trials with a reported enrollment target (411% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07067463, a Phase 3 study of Multiple Sclerosis (MS) Primary Progressive, is actively recruiting participants, sponsored by Zenas BioPharma (USA).
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 2
- Study locations
Study Summary
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orelabrutinib
Study Locations (2)
Florida
- Neurology Associates, PA - Maitland
South Carolina
- Premier Neurology - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2025-12 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07067463
The ClinicalTrials.gov registry entry for NCT07067463 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 138-participant average among 3 other Multiple Sclerosis (MS) Primary Progressive trials with a reported enrollment target (411% higher). The listed sponsor is Zenas BioPharma (USA), which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis (MS) Primary Progressive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07067463 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07067463 about?
NCT07067463 is a clinical study titled "A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis". Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum...
What is the current status of trial NCT07067463?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2025-12. Estimated completion is 2030-07.
What conditions does trial NCT07067463 study?
This clinical trial studies the following conditions: Multiple Sclerosis (MS) Primary Progressive.
What interventions are being tested in trial NCT07067463?
The interventions under investigation include: Placebo (DRUG), Orelabrutinib (DRUG).
Who is sponsoring clinical trial NCT07067463?
This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07067463 being conducted?
This trial has 2 study locations across Florida, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (MS) Primary Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.